PF-Atlas › Clinical Trials › NCT07671911
Idiopathic Pulmonary Fibrosis -Related Chronic Cough Reduction With Nalbuphine Extended-Release Tablets
NAL ER · Phase 3
Registry ID
NCT07671911
Phase
Phase 3
Status
Recruiting
Drug / intervention
NAL ER
Sponsor
Trevi Therapeutics
Start
2026-06-29
Enrollment
306
Locations
15
About this trial
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07671911 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.